E PERFLUORODECALIN/CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
RN 306-94-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN Naphthalene, 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluorodecahydro-
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Naphthalene, octadecafluorodecahydro- (6CI, 7CI, 8CI, 9CI)
OTHER NAMES:
CN APF 140
CN Decalin perfluoride
CN FDC
CN Flutec PP 5
CN Flutec PP 6
CN Flutec PP 7
CN NSC 97066
CN Octadecafluorodecahydronaphthalene
CN Octadecafluorodecalin
CN Perflunafene
CN Perfluorodecahydronaphthalene
CN Perfluorodecalin
CN PP 5
CN PP 6
DR 127964-38-9, 70323-33-0, 77115-10-7, 159813-90-8
MF C10 F18
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM,
CSNB, DDFU, DETHERM*, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA,
MEDLINE, MRCK*, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

SET EXPAND CONTINUOUS
L1 1 S E3
E PERFLUOROOCTYLBROMIDE/CN
E PERFLUOROOCTYL BROMIDE/CN
L2 1 S E27

```
     FILE 'HCAPLUS' ENTERED AT 17:14:30 ON 31 MAR 2010
L3          185 S L1 AND L2

     FILE 'REGISTRY' ENTERED AT 17:15:08 ON 31 MAR 2010
                E PERFLUOROTRIPROPYL AMINE/CN
L4            1 S E40

     FILE 'HCAPLUS' ENTERED AT 17:15:50 ON 31 MAR 2010
L5          259 S L4
L6           51 S L3 AND L5
L7           46 S L6 AND (PY<=2004 OR AY<=2004 OR PRY<=2004)
L8           13 S L6 AND PHOSPHOLIPID?
L9           12 S L8 AND (PY<=2004 OR AY<=2004 OR PRY<=2004)

L9   ANSWER 1 OF 12  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Method for production of synthetic perfluorocarbon blood
substitute
     compositions and other media based on perfluorocarbon emulsions
AB   The invention pertains to organic chemical, in particular method
     for production of perfluorocarbon emulsion capable of oxygen
     transfer. The claimed method provides perfluorocarbon emulsion by
     blending of total amount of perfluorocarbons with emulsifier such
     as proxanol-268 (or phospholipids) and multiple mixture
     homogenizing in high pressure homogenizer.  Said perfluorocarbon
     emulsion is obtained by stream-droplet passing of multicomponent
     perfluorocarbon mixture trough subsequently arranged main and
     addnl. (second) homogenizer circuits and buffer volume for
     pressure compensation arranged between these circuits, wherein
     abovementioned multicomponent perfluorocarbon mixture contains
     two, three, or four perfluorocarbons in specific ratio.  The
     mixture is concentrated to produce perfluoroorg. compds. (PFOC)
     from 1-100%, emulsified with proxanol-268 or phospholipid solution
     under pressure in both homogenizer circuits of 20-1500 atm and at
     cooling temperature of +15° to +60° followed by addition of
     electrolytes into obtained perfluorocarbon emulsion to produce
     finished therapeutical form.
ACCESSION NUMBER:         2007:1138735  HCAPLUS  Full-text
DOCUMENT NUMBER:          147:433710
TITLE:                    Method for production of synthetic
perfluorocarbon
                          blood substitute compositions and other media
based on
                          perfluorocarbon emulsions
INVENTOR(S):              Vorob'ev, S. I.
PATENT ASSIGNEE(S):       Russia
SOURCE:                   Russ., 7pp.
                          CODEN: RUXXE7
DOCUMENT TYPE:            Patent
LANGUAGE:                 Russian
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ----------          ----   --------    -------------------     ----
----
     RU 2307647           C2    20071010    RU 2004-136741
```

20041216 <--
PRIORITY APPLN. INFO.:   RU 2004-136741
20041216 <--
CC 63-7 (Pharmaceuticals)
IT 306-94-5P, Perfluorodecalin 311-89-7P, Perfluorotributylamine
    338-83-0P, Perfluorotripropylamine 423-55-2P,
    Perfluorooctyl bromide 86630-50-4P
    RL: IMF (Industrial manufacture); PEP (Physical, engineering or
chemical
    process); TEM (Technical or engineered material use); THU
(Therapeutic
    use); BIOL (Biological study); PREP (Preparation); PROC (Process);
USES
    (Uses)
       (production of synthetic perfluorocarbon blood substitute
compns. and other
       media based on perfluorocarbon emulsions)

L9 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Novel compositions useful for delivering anti-inflammatory agents
into a
    cell
AB The present invention is directed, inter alia, to compns. and
    their use for delivering compds. into a cell. In a preferred
    embodiment, the compns. comprise, in combination with the compound
    to be delivered, an organic halide, a targeting ligand, and a
    nuclear localization sequence, optionally in the presence of a
    carrier. Ultrasound may be applied, if desired. The compns. are
    particularly suitable for the treatment of inflammatory diseases.
ACCESSION NUMBER: 2000:755211 HCAPLUS Full-text
DOCUMENT NUMBER: 133:340208
TITLE: Novel compositions useful for delivering
                         anti-inflammatory agents into a cell
INVENTOR(S):   Unger, Evan C.; McCreery, Thomas; Sadewasser,
David A.
PATENT ASSIGNEE(S):   ImaRx Pharmaceutical Corp., USA
SOURCE: Eur. Pat. Appl., 78 pp.
                         CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

    PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
    ----------------   ----   --------   --------------------   ----
----
    EP 1046394   A2   20001025   EP 2000-303249
20000418 <--
    EP 1046394   A3   20011010
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
            IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.:   US 1999-294623   A
19990419 <--
IC ICM A61K009-127
    ICS A61K048-00; C12N015-88
CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 34
IT Cardiolipins
Glycolipids
Glycosphingolipids
Phospholipids, biological studies
Plasmalogens
Sphingolipids
Sphingomyelins
Sulfatides

L9 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
TI A method of increasing nucleic acid synthesis with ultrasound
AB The present invention is directed to a method of increasing nucleic acid synthesis in a cell comprising administering to the cell a therapeutically effective amount of ultrasound for a therapeutically effective time such that said administration of said ultrasound results in said increased nucleic acid synthesis. The nucleic acid sequence may comprise an endogenous sequence or an exogenous sequence. In particular, the invention is directed to increasing the expression of stress proteins and repair proteins.
ACCESSION NUMBER: 1999:350607 HCAPLUS Full-text
DOCUMENT NUMBER: 131:14825
TITLE: A method of increasing nucleic acid synthesis with ultrasound
INVENTOR(S): Unger, Evan C.; McCreery, Thomas; Sadewasser, David
PATENT ASSIGNEE(S): ImaRx Pharmaceutical Corp., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925385	A1	19990527	WO 1998-US23843	19981111 <--
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9913906	A	19990607	AU 1999-13906	19981111 <--
PRIORITY APPLN. INFO.:			US 1997-971540	A 19971117 <--
			WO 1998-US23843	W 19981111 <--

L9 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Oxygen delivery agents and uses for the same
AB The present invention describes, inter alia, oxygen delivery agents or blood substitutes comprising a fluorinated gas and a stabilizing material, uses for the oxygen delivery agents or blood

substitutes, and apparatus for making and delivering the oxygen delivery agents or blood substitutes. A lipid mixture containing dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylethanolamine, PEG-500, dipalmitoylphosphatidic acid in a solution of saline, glycerol, and propylene glycol was placed in a bottle. Air was evacuated from the bottle, then the bottle was filled with perfluorobutane to obtain perfluorobutane-entrapped liposomes.

ACCESSION NUMBER: 1999:9733 HCAPLUS Full-text
DOCUMENT NUMBER: 130:71628
TITLE: Oxygen delivery agents and uses for the same
INVENTOR(S): Unger, Evan C.; McGreery, Thomas; Wu, Yunqiu
PATENT ASSIGNEE(S): ImaRx Pharmaceutical Corp., USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857670	A1	19981223	WO 1998-US12011	19980610 <--
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6537246	B1	20030325	US 1997-877826	19970618 <--
EP 1015039	A1	20000705	EP 1998-928973	19980610 <--
EP 1015039	B1	20080827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 406179	T	20080915	AT 1998-928973	19980610 <--
US 20030120204	A1	20030626	US 2003-336906	20030106 <--
US 7105151	B2	20060912		
US 20070059248	A1	20070315	US 2006-514729	20060831 <--

PRIORITY APPLN. INFO.:
US 1997-877826 A 19970618 <--
WO 1998-US12011 W 19980610 <--
US 2003-336906 A1 20030106 <--

L9 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Acoustically active drug delivery systems comprising a gas or gaseous precursor filled microsphere
AB The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphere

wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound Methods of preparing the targeted therapeutic delivery systems are also embodied by the present invention which comprise processing a solution comprising an oil and a surfactant in the presence of a gaseous precursor, at a temperature below the gel to liquid crystalline phase transition temperature of the surfactant to form gas or gaseous precursor filled microsphere, and adding to said microspheres a therapeutic compound resulting in a targeted therapeutic delivery system, wherein said processing is selected from the group consisting of controlled agitation, controlled drying, and a combination thereof. Thus, 1.5 mL of MRX115 precursor was mixed with 320 μL soybean oil followed by addition of dipalmitoyl phosphoethanolamine to the soybean oil at a concentration of 0.5 mg/mL. The mixture was placed into a vial and the headspace removed and replaced with perfluorobutane and was shaken for 60 s. The acoustically active lipospheres thus obtained had particle size of 1.67-3.49 μm.

ACCESSION NUMBER: 1998:766508 HCAPLUS Full-text
DOCUMENT NUMBER: 130:29222
TITLE: Acoustically active drug delivery systems comprising a gas or gaseous precursor filled microsphere
INVENTOR(S): Unger, Evan C.
PATENT ASSIGNEE(S): ImaRx Pharmaceutical Corp., USA
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851284	A1	19981119	WO 1998-US9569	19980512 <--
W: AU, BR, CA, CN, JP, KR, NZ				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6416740	B1	20020709	US 1998-75343	19980511 <--
AU 9877961	A	19981208	AU 1998-77961	19980512 <--
EP 981333	A1	20000301	EP 1998-926033	19980512 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001524983	T	20011204	JP 1998-549372	19980512 <--
US 20020159952	A1	20021031	US 2002-84855	20020227 <--
US 20040091541	A1	20040513	US 2003-622027	20030716 <--

PRIORITY APPLN. INFO.: US 1997-46379P P
19970513 <--
US 1998-75343 A
19980511 <--
US 1998-75477 B3
19980511 <--
WO 1998-US9569 W
19980512 <--
US 2001-828762 B1
20010409 <--

L9 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Oil-in-water emulsions containing contrast agents
AB Oil-in-water emulsions in which the oil phase comprises condensed or dissolved oil-soluble gas/fluid or gas precursor are useful as ultrasound contrast agents. Such products contain insignificant amts. of free gas bubbles or microbubbles in their stored form and exhibit good storage stability, but may be designed to promote rapid microbubble generation immediately before or upon administration. An emulsion was prepared from 0.1021 g Span 20, 10 mL n-pentane, 0.5466 g Tween 60, and 40 mL water. Above emulsion 2 mL, was injected into 5 mL water at 37° to obtain an ultrasound attenuation which was stable for 20 min.
ACCESSION NUMBER: 1994:686621 HCAPLUS Full-text
DOCUMENT NUMBER: 121:286621
ORIGINAL REFERENCE NO.: 121:52215a,52218a
TITLE: Oil-in-water emulsions containing contrast agents
INVENTOR(S): Berg, Arne; Dugstad, Harald; Foss, Per Antonius; Klaveness, Jo; Oestensen, Jonny; Rongved, Paal; Strande, Per
PATENT ASSIGNEE(S): Holmes, Michael John, UK; Nycomed Imaging A.S
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9421301	A1	19940929	WO 1994-GB521	19940316 <--
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2158365	A1	19940929	CA 1994-2158365	

19940316 <--
AU 9462152 A 19941011 AU 1994-62152
19940316 <--
AU 696091 B2 19980903
BR 9406228 A 19951212 BR 1994-6228
19940316 <--
EP 689461 A1 19960103 EP 1994-909226
19940316 <--
EP 689461 B1 20000705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
CN 1121315 A 19960424 CN 1994-191801
19940316 <--
CN 1066963 C 20010613
HU 72982 A2 19960628 HU 1995-2694
19940316 <--
JP 08509706 T 19961015 JP 1994-520775
19940316 <--
JP 3787639 B2 20060621
PL 175128 B1 19981130 PL 1994-310656
19940316 <--
RU 2128520 C1 19990410 RU 1995-121645
19940316 <--
AT 194292 T 20000715 AT 1994-909226
19940316 <--
ES 2147784 T3 20001001 ES 1994-909226
19940316 <--
FI 9504325 A 19951011 FI 1995-4325
19950914 <--
NO 9503637 A 19950915 NO 1995-3637
19950915 <--
HK 1004981 A1 20010511 HK 1998-104117
19980513 <--
US 20010019710 A1 20010906 US 2000-729341
20001205 <--
PRIORITY APPLN. INFO.: GB 1993-5349 A
19930316 <--
WO 1994-GB521 W
19940316 <--
US 1995-468742 B1
19950606 <--
US 1998-200731 B1
19981127 <--
IC ICM A61K049-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 8
IT Phospholipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(egg yolk; oil-in-water emulsions containing contrast ultrasound agents)
IT 56-81-5, 1,2,3-Propanetriol, biological studies 75-76-3, Tetramethylsilane 109-66-0, n-Pentane, biological studies 110-00-9,
Furan 112-30-1, Decanol 151-21-3, Sodium dodecyl sulfate, biological
studies 288-13-1, Pyrazole 306-94-5, Perfluorodecalin 338-83-0, Perfluorotripropylamine 355-25-9, Perfluorobutane

423-55-2, Perfluorooctyl bromide 629-25-4, Sodium dodecanoate
1338-39-2, Span 20 2551-62-4 3282-73-3,
Didodecyldimethylammonium
bromide 7440-63-3, Xenon, biological studies 7664-93-9D,
Sulfuric
acid, alkali metal salts and alkyl derivs. 7722-84-1, Hydrogen
peroxide,
biological studies 7784-42-1, Arsine 7803-62-5, Silane,
biological
studies 9003-11-6, Polyoxyethylene-polyoxypropylene copolymer
9005-67-8, Tween 60 12441-09-7D, Sorbitan, esters with fatty
acids
14343-69-2, Azide 27988-97-2, Tetrazole 36118-45-3, Pyrazoline
125003-34-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oil-in-water emulsions containing contrast ultrasound agents)
OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE
THIS RECORD
(13 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE
FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L9 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Stabilization of fluorocarbon emulsions
AB Storage-stable fluorocarbon emulsions comprise a continuous aqueous phase and a discontinuous fluorocarbon phase, in which the fluorocarbon phase comprises a major amount of a first fluorocarbon or fluorocarbon mixture, and a minor amount of a second fluorocarbon or fluorocarbon mixture, in which the second fluorocarbon has a mol. weight greater than that of the first fluorocarbon and the second fluorocarbon includes a lipophilic moiety in its structure, whereby the second fluorocarbon serves to promote particle size stability in the emulsion while simultaneously providing favorably short organ retention times when administered to animals in vivo. For example, a stable emulsion contained perfluorodecalin 58.2, perfluorodecyl bromide 10, and egg yolk phospholipid 4.6 % (weight/volume).
ACCESSION NUMBER: 1994:442774 HCAPLUS Full-text
DOCUMENT NUMBER: 121:42774
ORIGINAL REFERENCE NO.: 121:7693a,7696a
TITLE: Stabilization of fluorocarbon emulsions
INVENTOR(S): Weers, Jeffry Greg; Klein, David Henry;
Johnson, Cindy
Shizuko
PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     WO 9409625           A2    19940511    WO 1993-US10286
19931027 <--
         W:  AU, CA, JP
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
     US 5628930           A     19970513    US 1992-967700
19921027 <--
     CA 2146757           A1    19940511    CA 1993-2146757
19931027 <--
     CA 2146757           C     20040921
     AU 9455878           A     19940524    AU 1994-55878
19931027 <--
     AU 678418            B2    19970529
     EP 666736            A1    19950816    EP 1994-901211
19931027 <--
     EP 666736            B1    19961218
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC,
NL, PT, SE
     JP 08502753          T     19960326    JP 1994-511273
19931027 <--
     JP 3854630           B2    20061206
     AT 146358            T     19970115    AT 1994-901211
19931027 <--
     ES 2095739           T3    19970216    ES 1994-901211
19931027 <--
     US 5914352           A     19990622    US 1997-854547
19970512 <--
     US 6204296           B1    20010320    US 1999-263924
19990305 <--
     US 20020065326       A1    20020530    US 2001-7053
20011203 <--
     US 20040068020       A1    20040408    US 2003-430198
20030505 <--
     US 20050256211       A9    20051117
     JP 2006160742        A     20060622    JP 2005-352110
20051206 <--
PRIORITY APPLN. INFO.:                       US 1992-967700      A
19921027 <--
                                             JP 1994-511273      A3
19931027 <--
                                             WO 1993-US10286     W
19931027 <--
                                             US 1997-854547      A1
19970512 <--
                                             US 1999-263924      A1
19990305 <--
                                             US 2000-659516      A1
20000912 <--
                                             US 2001-7053        B1
20011203 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IC   ICM  A01N
CC   63-6 (Pharmaceuticals)
IT   Phospholipids, biological studies
     RL: BIOL (Biological study)
        (egg yolk, fluorocarbon emulsions containing, for therapeutic
and
```

diagnostic use)
IT 306-94-5, Perfluorodecalin 307-43-7, Perfluorodecyl bromide
335-56-8, Perfluorohexyl bromide 338-83-0,
Perfluorotripropylamine 423-55-4, Perfluorooctyl bromide
2342-01-0 30389-25-4 62375-54-6, Perfluoro-2,2,4,4-
tetramethylpentane
63267-58-3 75108-51-9 77117-48-7 84551-43-9,
Bis(perfluorobutyl)ethene 97148-70-4 98983-13-2 147265-65-4
154478-87-2 156186-26-4 156186-27-5 156186-28-6
RL: BIOL (Biological study)
(fluorocarbon emulsions containing, for therapeutic and
diagnostic use)
OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE
THIS RECORD
(7 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE
FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L9 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Effects of lipid emulsifiers on the properties of perfluoro
organic
emulsions
AB Phospholipid emulsifying agents did not alter physicochem. and
biol. properties (O carrying ability) of emulsions containing
perfluoro compds. However, in emulsions stabilized with
phospholipids, the partial O pressure was increased compared to
those containing Pluronic F 68. Emulsions containing
perfluorooctyl bromide and perfluoromethyladamantine were the most
promising ones for clin. uses, since they are stable at room
temperature and showed superior physicochem. and biol. properties.
ACCESSION NUMBER: 1991:49532 HCAPLUS Full-text
DOCUMENT NUMBER: 114:49532
ORIGINAL REFERENCE NO.: 114:8453a,8456a
TITLE: Effects of lipid emulsifiers on the properties
of
perfluoro organic emulsions
AUTHOR(S): Oksinoid, O. E.; Romanova, M. Zh.; Afonin, N.
I.
CORPORATE SOURCE: Vses. Nauchno-Issled. Inst. Krovezamenitelei
Gorm.
Prep., Moscow, USSR
SOURCE: Vestnik Akademii Meditsinskikh Nauk SSSR (1990
), (8), 37-41
CODEN: VAMNAQ; ISSN: 0002-3027
DOCUMENT TYPE: Journal
LANGUAGE: Russian
CC 63-7 (Pharmaceuticals)
ST perfluoro emulsion phospholipid emulsifying agent
IT Perfluoro compounds
RL: BIOL (Biological study)
(emulsions, phospholipid-stabilized, properties of, for blood
substitutes)
IT Emulsions
(perfluoro compound, phospholipid-stabilized, properties of,
for blood substitutes)

IT Blood substitutes and Plasma expanders
(perfluoro emulsions as, phospholipid-stabilized, properties of)
IT Cardiolipins
Phosphatidylcholines, biological studies
Phosphatidylinositols
Phosphatidylserines
Phospholipids, biological studies
Sphingomyelins
RL: BIOL (Biological study)
(perfluoro emulsions stabilized by, properties of, as blood substitutes)
IT Emulsifying agents
(phospholipids as, for perfluoro emulsions, for blood substitutes)
IT 7782-44-7, Oxygen, biological studies
RL: BIOL (Biological study)
(carriers, perfluoro emulsions stabilized with phospholipids as, properties of)
IT 306-94-5, Perfluorodecaline 338-83-0, Perfluorotripropylamine 423-55-2, Perfluorooctylbromide 812-47-5, Perfluorobutylamine 60096-00-6
RL: BIOL (Biological study)
(emulsions, phospholipid-stabilized, properties of, for blood substitutes)
IT 106392-12-5, Pluronic F 68
RL: BIOL (Biological study)
(perfluoro emulsions stabilized by, properties of, phospholipid emulsifying agents in relation to)
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L9 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
TI A perfluorochemical emulsion as an oxygen carrier
AB To increase the stability of emulsions of perfluoro compds. (blood substitutes), a series of expts. were conducted on the stability, tissue half-life and toxicity of a number of perfluoro compds. which could be stored in the liquid state for a long time and yet retain their O-transporting capability. The stability of the emulsion was evaluated by determining the average particle size after heating at 100° for 30 min and after a 4-wk storage at 4°. The mol. size and presence of hetero atoms in the perfluorochem. affected the excretion rate and emulsion stability. Perfluoro-4-methyloctahydroquinolidizine (FMOQ) [86563-85-1] emulsified with a mixture of 2% pluronic F-68 [9003-11-6] and 20% yolk phospholipid is more stable than the known 20% Fluosol-DA and all the other perfluoro compds. studied. The FMOQ emulsion can be sterilized by heating and stored at 4° for >6 mo. without deterioration. The elimination rate of FMOQ was 5-fold higher than that of perfluorotripropylamine [338-83-0] and similar to that of perfluorodecalin [306-94-5]. The half-life rat tissues was 7 days. All of the rats exchange-transfused with FMOQ at a hematocrit of 4% survived and the hematocrit and Hb levels normalized rapidly. Three mo after the exchange transfusion, no histol. changes were observed even in the liver and spleen, although a small amount of FMOQ was detected in these organs.

ACCESSION NUMBER: 1984:412153 HCAPLUS Full-text
DOCUMENT NUMBER: 101:12153
ORIGINAL REFERENCE NO.: 101:1921a,1924a
TITLE: A perfluorochemical emulsion as an oxygen carrier
AUTHOR(S): Yokoyama, Kazumasa; Suyama, Tadakazu; Okamoto, Hiroyuki; Watanabe, Masahiro; Ohyanagi, Harumasa; Saitoh, Yoichi
CORPORATE SOURCE: Green Cross Corp., Osaka, Japan
SOURCE: Artificial Organs (1984), 8(1), 34-40
CODEN: ARORD7; ISSN: 0160-564X
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 63-7 (Pharmaceuticals)
Section cross-reference(s): 1
IT Phospholipids
RL: BIOL (Biological study)
(perfluoro compds. in blood substitute emulsions stabilization with)
IT 306-94-5 307-34-6 308-95-2 311-89-7 335-36-4
338-83-0 374-59-4 374-80-1 378-33-6 423-55-2
424-20-4 464-36-8 514-03-4 6792-31-0 36481-20-6 51294-16-7
56523-43-4 67711-54-0 68697-63-2 69064-33-1 69661-30-9
72942-63-3 73900-70-6 78522-49-3 84551-43-9 84814-04-0
86563-85-1 86714-20-7 86714-21-8 86714-22-9 86714-23-0
86714-24-1 86714-25-2 86714-26-3 86714-27-4 86714-28-5
86714-29-6 86714-30-9 86714-31-0 86714-32-1 86714-35-4
86714-36-5 86714-38-7 86729-63-7 87018-52-8 87042-39-5
90375-75-0 90375-76-1 90375-77-2
RL: BIOL (Biological study)
(blood substitute emulsions, stability and excretion of)

FILE 'HCAPLUS' ENTERED AT 17:19:08 ON 31 MAR 2010
L10 1 S US 20070197475/PN

FILE 'REGISTRY' ENTERED AT 17:19:45 ON 31 MAR 2010
L11 1 S 864160-31-6/RN

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
RN 864160-31-6 REGISTRY
CN 2-Pyrrolidinone, 3,4,5,5-tetrafluoro-1-(1,1,2,2,3,3,3-heptafluoropropyl)-3,4-bis(trifluoromethyl)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Pyrrolidinone, 3,4,5,5-tetrafluoro-1-(heptafluoropropyl)-3,4-bis(trifluoromethyl)- (9CI)
MF C9 F17 N O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PROC (Process); USES

(Uses)



```
                SET NOTICE 1 DISPLAY
                SET NOTICE LOGIN DISPLAY

     FILE 'HCAPLUS' ENTERED AT 17:19:55 ON 31 MAR 2010
L12           1 S L11

     INDEX '1MOBILITY, 2MOBILITY, ABI-INFORM, ADISCTI, AEROSPACE,
AGRICOLA,
     ALUMINIUM, ANABSTR, ANTE, APOLLIT, AQUALINE, AQUASCI, AQUIRE,
BABS,
     BIBLIODATA, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO,
CABA,
     CAPLUS, CASREACT, CBNB, CEABA-VTB, CERAB, CHEMINFORMRX,' ENTERED
AT
     17:20:08 ON 31 MAR 2010
                SEA L11
                ---------
                0*  FILE 1MOBILITY
                0*  FILE 2MOBILITY
                0*  FILE ABI-INFORM
                0*  FILE ADISCTI
                0*  FILE AEROSPACE
                0*  FILE AGRICOLA
                0*  FILE ALUMINIUM
                0*  FILE ANABSTR
                0*  FILE ANTE
                0*  FILE APOLLIT
                0*  FILE AQUALINE
                0*  FILE AQUASCI
                0*  FILE BABS
                0*  FILE BIBLIODATA
                0*  FILE BIOENG
                0*  FILE BIOSIS
                0*  FILE BIOTECHABS
                0*  FILE BIOTECHDS
                0*  FILE BIOTECHNO
                0*  FILE CABA
                1   FILE CAPLUS
                0*  FILE CASREACT
                0*  FILE CEABA-VTB
                0*  FILE CERAB
                0*  FILE CHEMINFORMRX
                0*  FILE CIN
                0*  FILE CIVILENG
                0*  FILE COMPENDEX
                0*  FILE COMPUAB
```

0* FILE COMPUSCIENCE
0* FILE CONFSCI
0* FILE COPPERLIT
0* FILE CORROSION
0* FILE CROPB
0* FILE CSNB
0* FILE DDFB
0* FILE DGENE
0* FILE DISSABS
0* FILE DKF
0* FILE DRUGB
0* FILE ELCOM
0* FILE EMA
0* FILE EMBAL
0* FILE EMBASE
0* FILE ENERGY
0* FILE ENVIROENG
0* FILE EPFULL
0* FILE ESBIOBASE
0* FILE FOMAD
0* FILE FRANCEPAT
0* FILE FRFULL
0* FILE FROSTI
0* FILE FSTA
0* FILE GBFULL
0* FILE GENBANK
0* FILE GEOREF
0* FILE HEALSAFE
0* FILE IFICLS
0* FILE IFIPAT
0* FILE IMSDRUGNEWS
0* FILE INFODATA
0* FILE INIS
0* FILE INPADOCDB
0* FILE INPAFAMDB
0* FILE INSPEC
0* FILE INSPHYS
0* FILE IPA
0* FILE ITRD
0* FILE JAPIO
0* FILE KOREAPAT
0* FILE KOSMET
0* FILE LIFESCI
0* FILE LISA
0* FILE MATBUS
0* FILE MECHENG
0* FILE MEDLINE
0* FILE METADEX
0* FILE NAPRALERT
0* FILE NLDB
0* FILE NTIS
0* FILE OCEAN
0* FILE PASCAL
0* FILE PATDD
0* FILE PATDPA
0* FILE PATDPAFULL
0* FILE PCI

```
                0*  FILE PCTFULL
                0*  FILE PCTGEN
                0*  FILE PIRA
                0*  FILE POLLUAB
                0*  FILE PROMT
                0*  FILE RDISCLOSURE
                0*  FILE RUSSIAPAT
                0*  FILE SCISEARCH
                0*  FILE FORIS
                0*  FILE SOLIDSTATE
                0*  FILE SOLIS
                0*  FILE SYNTHLINE
                0*  FILE TEMA
                0*  FILE TEXTILETECH
                0*  FILE TOXCENTER
                0*  FILE TRIBO
                0*  FILE TULSA
                0*  FILE TULSA2
                0*  FILE UFORDAT
                0*  FILE ULIDAT
                0*  FILE USGENE
                2   FILE USPATFULL
                0*  FILE VETB
                0*  FILE WATER
                0*  FILE WELDASEARCH
                0*  FILE WPIDS
                0*  FILE WPIFV
                0*  FILE WPINDEX
                0*  FILE WSCA
                0*  FILE WTEXTILES
L13              QUE L11
                 ---------

     FILE 'REGISTRY' ENTERED AT 17:21:03 ON 31 MAR 2010
                  E PERFLUORO-N-METHYLCYCLOHEXYLPIPERIDINE/CN

     FILE 'REGISTRY' ENTERED AT 17:21:49 ON 31 MAR 2010
L14              1 S 96009-97-1/RN


L14  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   96009-97-1  REGISTRY
CN   Piperidine, 2,2,3,3,4,5,5,6,6-nonafluoro-1-(1,1,2,2,3,3,3-
     heptafluoropropyl)-4-(trifluoromethyl)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Piperidine, 2,2,3,3,4,5,5,6,6-nonafluoro-1-(heptafluoropropyl)-4-
     (trifluoromethyl)- (9CI)
MF   C9 F19 N
LC   STN Files:   BEILSTEIN*, CA, CAPLUS, SPECINFO, TOXCENTER,
USPATFULL
        (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PROC (Process);
USES
       (Uses)
RL.NP  Roles from non-patents:  PREP (Preparation)
```



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'HCAPLUS' ENTERED AT 17:22:37 ON 31 MAR 2010
L15 0 S L8 AND L14